As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer's markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly studied. Methylation of Reprimo promoter is a repetitive procedure exclusive to cancer which nullifies its expression and performance. The present research seeks to study the expression and methylation of Reprimo among people suffering with gastric cancer so that it may be used as a biomarker for early diagnosis. Fifty blood samples taken from healthy people (normal samples) and 50 blood samples obtained from gastric cancer patients were analyzed using Real-Time PCR. The methylation status of the promoter of Reprimo was studied using Methylation Specific PCR technique in normal samples and in gastric cancer Iranian patients. We observed reduction in expression rate of Reprimo in the blood samples of patients suffering with gastric cancer in comparison to normal blood samples. A significant correlation was also observed between the expression rate of this gene, age and methylation of its promoter among patients suffering with gastric cancer and various analysis points to a correlation between reduced expressions of Reprimo gene in gastric cancer patients. In conclusion, reduced expression of Reprimo gene and greater levels of methylation of its promoter seems to be promising biomarkers for early diagnosis of gastric cancer.
Gastric cancer is the 5th most common type of cancer in the world with a mortality rate of 723000 cases reported in 2012 throughout the world rendering it as the third main cause of mortality as a result of cancer.
1 Reprimo (RPRM) gene acts as a potential suppressor of P53-dependent tumor signaling pathway. It encodes a highly glycosilated protein mostly found in cytoplasm. 2, 3 Reprimo is one of the genes responsible for regulation of development and growth of normal cells. 4 Deactivation of Reprimo gene usually takes place in initial phases of various tumors mostly as a result of DNA methylation. 5 It has been greatly observed that in two cell categories of gastric cancer without Reprimo methylation, weak expression in normal conditions and high expression in cases of DNA damage were observed. 6 Expression of Reprimo is usually stimulated in response to damages caused to DNA, but expression of Reprimo wipes out the expression and effects of this gene. 6, 7 As a result, this gene acts as a suppressive agent for tumor growth in gastric cancer. Clinical assessment of methylation of Reprimo promoter may be used as an indicator of invasive tumors, and thus as an indicator for chemotherapy. 8 Although it is of significant importance for better management of gastric cancer, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly analyzed. Thus, the present research seeks to study the correlation between methylation and expression rate of Reprimo gene in gastric cancer.
Materials and Methods
The present research studied as many as 100 venous blood samples including 50 healthy blood samples (normal samples) and 50 blood samples obtained from gastric cancer patients. Proper samples were obtained from Masoud Medical Diagnostic Laboratory (Iran) collected from 2013 to 2015 in test tubes containing EDTA. The individuals studied aged 16 to 86 years old.
Twentysix samples were from female and the remaining sevetyfour from male subjects. 40 samples were older than 55 years, while the remaining 60 were younger than 55. All participating patients in this study were in the early stages of gastric cancer. They had been referred to the doctor with stomach ache, diarrhea and vomiting. 
Carrying out Real-Time PCR
Using the sequences in NCBI gene bank, the primers required for Reprimo genes and GAPDH were designed and studied using Gene Runner software. The designed primer had a 100% match with sequences and it was used in Iran for the first time ( Table 1 ). The mixture of RealTime PCR contained 10μl of master mix obtained from Sinagen Co. (Iran), 0.5μl forward primer (0.4mM), 0.5μl of reverse primer (0.4 mM), 1μl of cDNA sample, and 8μl of distilled water with a total volume of 20μl. The following thermal plan was designed for PCR reaction using Reprimo primer: 10 minutes of initial denaturation in a temperature of 95℃ for 1 cycle, 40 cycles of exposure to a temperature of 95 ℃ each lasting 15 seconds, and 1 minute of exposure to 64.6 ℃ of annealing. The following thermal plan was defined for PCR reaction using GAPDH primers as internal controls:
10 minutes of initial denaturation in a temperature of 95℃ for 1 cycle, 45 cycles of exposure to a temperature of 95℃ for 15 seconds, 30 seconds of exposure to an annealing temperature of 59℃. In the end, the analysis of data obtained through Real-Time PCR was carried out based upon the threshold cycle obtained for target and reference genes. The difference between the average of reference Ct gene and target Ct gene was calculated as an indicator of ∆Ct for both test and control groups. To study the specificity of primers and cyber green fluorescence color and assuring the proliferation of exclusive parts and making sure there are no non-specific particles and Dimer-Primer in PCR product, the melting curve was drawn for Reprimo and GAPDH genes separately using
Step One Real-Time PCR Applied Biosystems ( Figures  1 and 2 ). The linear charts of Reprimo and GAPDH genes proliferation curve were drawn by assessing the changes in the fluorescence level using
Step One Real-Time PCR Applied Biosystems (Figures 3 and 4) . 
MS-PCR to diagnose the methylated and non-methylated areas
In designing the primers for carrying out MS-PCR (Methylation Specific PCR), those primers designed for the regions containing methylated cytosines begin with letter G, while those designed for areas containing nonmethylated cytosines begin with letter T. Two pairs of primers were designed for this purpose: 1 pair of methylated primer and 1 pair of non-methylated primer ( 
Results and Discussion
The results of the expression rate of Reprimo gene Ct of samples was calculated by the machine following the proliferation reaction and it was converted to RQ (Quantification Relative) of expression rate. Graph of the results was drawn by Graph Pad Prism software (Fig. 5 ).
The majority of gastric patients exhibited a reduced Reprimo gene expression rate compared to normal cases. In this case, the average of normal samples was set to 1 by machine analysis. As it was expected from Reprimo Gene as a suppressive tumor in gastric cancer, the expression rate of this gene in normal samples was much more than what was observed in the majority of samples suffering with gastric cancer. This correlation is significant as P-value < 0.05. The average of expression of gastric patients is much less than what was observed in normal samples. This comparison is a significant correlation considering the p-value (Fig. 10 ). An analysis
Fig 10. Mean RQ of Reprimo gene based upon methylation status

Fig 9. Example of MS-PCR results obtained using methylated primers. The samples with a band size of 158 bp have methylation in the region of Reprimo gene promoter
Fig 8. Analysis of expression rate of Reprimo gene among sick cases based upon their gender (p ≤ 0.960))
of results revealed that the expression rate of Reprimo gene among sick cases compared to healthy people (normal samples) younger than 55 is 1.206 while this value among those older than 55 was 0.673. This classification is solely based upon people's age group. As it is evident in chart 3, the mean expression rate of patients younger than 55 is statistically significant (Fig.  7) . The expression rate of Reprimo gene among male patients was nearly equal to what was observed among female patients and the mean RQ level of men and women was 0.785 and 0.774 respectively (Fig 8) .
Considering chart 4, we may conclude that gender has no influence on the expression rate of Reprimo and pathogenicity of gastric cancer.
The results of MS-PCR using methylated primers
Having carried out MS-PCR using methylated primers on 100 intended samples in order to study the methylation status of Reprimo gene promoter, it turned out that 23 samples out of the total 50 DNA samples of patients were methylated, but this number in normal cases was only 7.
As a result, 45.7% of samples for Reprimo gene promoter are methylated (Fig. 9) . The expression rate of Reprimo gene in non-methylated samples turned out to be 99.6% while this value in methylated samples was 54%. The mean expression rate of Reprimo gene in non-methylated samples is more than what was observed in methylated samples.
Although recognition of factors such as helicobacter pylori and various environmental factors has helped reduce the prevalence of gastric cancer, it is still one of the most common types of cancers in the world and constitutes a major clinical challenge. 9 Gastric cancer is one of the most important causes of mortality in developing countries. 10 As a result of ineffectiveness of most common treatments, the majority of patients have a low survival rate even after treatment and pass away. Various studies have pointed to the fact that various factors such as helicobacter pylori infection and its resulting side effects and other factors such as genetics and its resulting polymorphism may have a major influence on sensitivity and development of gastric cancer. 11 The multi-factor nature of gastric cancer makes it impossible to come up with an accurate prohibition strategy and to diagnose it quickly. As the majority of gastric cancer cases have no symptoms until they reach the advanced level, early diagnosis of gastric cancer is very difficult. 12 The first documented epigenetic change in gastric cancer is hyper-methylation of the promoter of genes that restore inconsistent nucleotide mutations of DNA. 13 Several genes have been described as tumor repressors deactivated as a result of hyper-methylation in gastric cancer. Although recent reports point to the discovery of methylation of particular genes, no comprehensive characteristic of DNA methylation in gastric cancer has been reported to this date. Bernal et al started a research to find a gene with inappropriate hypermethylation which is useful for early diagnosis. 15 By 16 By studying 39 patients with an average age of older than 64 and a men to woman ration of 1.3 to 1 and comparing them against normal control samples, Alejandro et al arrived at the conclusion that Reprimo is superior in diagnosing non-invasive genes than CEA and CA 19_9. Sensitivity, specificity, positive predictive value, negative predictive value, and the rate of positive possibilities may be a great progress in assessing the diagnostic effect of Reprimo for noninvasive diagnosis of gastric cancer. 17 Considering the important effect of Reprimo gene in preventing gastric cancer and as a repressor in early diagnosis of gastric cancer among those suffering with it, we decided to study the expression rate of this gene in the blood sample of those suffering with gastric cancer in Iran. This project is the first comprehensive research studying the expression rate of gene in the blood samples obtained from those suffering with gastric cancer in Iran. Using Real Time PCR based upon cyber-green of RPRM gene expression and utilizing MS-PCR technique, the methylation status of Reprimo gene promoter was studied. As the results of this research showed, the expression rate of RPRM gene in the blood samples obtained from patients is much less than what is observed in normal blood samples. Considering that all patients with gastric cancer who participated in this study were in the early stages of cancer, based on our results, the study of Reprimo gene hypermethylation can be useful in early diagnosis of gastric cancer. Our results are in line with those reported by Kathleen Saavedra et al. pointing that Reprimo gene is a tumor repressor and its methylation in the blood samples obtained from those suffering with gastric cancer is much higer than what we see in healthy individuals (45.7% of patients constituting a significant correlation). It can also act as a biomarker for early diagnosis of gastric cancer. There is also a significant correlation between expression rate of Reprimo and the age of people suffering with cancer and the methylation status of its promoter. On the hoter hand, the correlation between the expression rate of Reprimo gene and the gender of those suffering with cancer was far from being significant. 
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